{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T23:17:36Z","timestamp":1788650256606,"version":"build-2803163510"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.bbr.2023.114367","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T15:37:12Z","timestamp":1678117032000},"page":"114367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Serotonin in synucleinopathies"],"prefix":"10.1016","volume":"445","author":[{"given":"Ohnmar","family":"Hsam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zacharias","family":"Kohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbr.2023.114367_bib1","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/bs.pbr.2020.11.001","article-title":"Serotonergic imaging in Parkinson's disease","volume":"261","author":"de Natale","year":"2021","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.bbr.2023.114367_bib2","series-title":"Chapter 50 \u2013 Serotonin in Parkinson's disease, Handbook of Behavioral Neuroscience","first-page":"969","author":"Kohl","year":"2020"},{"key":"10.1016\/j.bbr.2023.114367_bib3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2147\/JEP.S265282","article-title":"Pathophysiological mechanisms and experimental pharmacotherapy for L-dopa-induced dyskinesia","volume":"13","author":"Fabbrini","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"10.1016\/j.bbr.2023.114367_bib4","series-title":"Handbook of the Behavioral Neurobiology of Serotonin","first-page":"3","author":"Azmitia","year":"2020"},{"key":"10.1016\/j.bbr.2023.114367_bib5","series-title":"Handbook of the Behavioral Neurobiology of Serotonin","first-page":"41","author":"Commons","year":"2020"},{"key":"10.1016\/j.bbr.2023.114367_bib6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1742-4682-7-34","article-title":"Serotonin synthesis, release and reuptake in terminals: a mathematical model","volume":"7","author":"Best","year":"2010","journal-title":"Theor. Biol. Med. Model."},{"key":"10.1016\/j.bbr.2023.114367_bib7","series-title":"Handbook of the Behavioral Neurobiology of Serotonin","first-page":"23","author":"Soiza-Reilly","year":"2020"},{"key":"10.1016\/j.bbr.2023.114367_bib8","unstructured":"M.T.\u00a0Vilar\u00f3, et al., Handbook of Behavioral Neuroscience, Volume 31, Chapter 6, pp. 121\u2013146. \u3008doi.org\/10.1016\/B978-0-444-64125-0.00006-2\u3009."},{"issue":"8","key":"10.1016\/j.bbr.2023.114367_bib9","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","article-title":"Parkinson's disease: etiopathogenesis and treatment","volume":"91","author":"Jankovic","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"12","key":"10.1016\/j.bbr.2023.114367_bib10","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbr.2023.114367_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41531-021-00273-9","article-title":"Lewy body disease or diseases with Lewy bodies?","volume":"8","author":"Men\u0161\u00edkov\u00e1","year":"2022","journal-title":"npj Park. Dis."},{"key":"10.1016\/j.bbr.2023.114367_bib12","unstructured":"I.G. McKeith, B.F. Boeve, D.W. Dickson, G. Halliday, J.P. Taylor, D. Weintraub, K. Kosaka, Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium, Neurology, 89(1), 2017, pp. 88\u2013100."},{"issue":"6","key":"10.1016\/j.bbr.2023.114367_bib13","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/mds.29005","article-title":"The movement disorder society criteria for the diagnosis of multiple system atrophy","volume":"37","author":"Wenning","year":"2022","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/j.bbr.2023.114367_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13024-021-00501-z","article-title":"Neuropathology and molecular diagnosis of synucleinopathies","volume":"16","author":"Koga","year":"2021","journal-title":"Mol. Neurodegener."},{"issue":"1\u20133","key":"10.1016\/j.bbr.2023.114367_bib15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0022-510X(89)90219-0","article-title":"Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome)","volume":"94","author":"Papp","year":"1989","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.bbr.2023.114367_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autneu.2017.11.002","article-title":"The neuropathology of multiple system atrophy and its therapeutic implications","volume":"211","author":"Valera","year":"2018","journal-title":"Auton. Neurosci. Basic Clin."},{"issue":"6","key":"10.1016\/j.bbr.2023.114367_bib17","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00401-010-0672-3","article-title":"Papp-Lantos inclusions and the pathogenesis of multiple system atrophy: an update","volume":"119","author":"Jellinger","year":"2010","journal-title":"Acta Neuropathol."},{"issue":"6","key":"10.1016\/j.bbr.2023.114367_bib18","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2990.2007.00907.x","article-title":"Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy","volume":"33","author":"Trojanowski","year":"2007","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.bbr.2023.114367_bib19","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/nrneurol.2015.197","article-title":"Pathogenesis of Parkinson disease\u2013the gutbrain axis and environmental factors","volume":"11","author":"Klingelhoefer","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.bbr.2023.114367_bib20","article-title":"The gut-brain axis and its relation to Parkinson\u2019s disease: a review, Front","volume":"13","author":"Klann","year":"2022","journal-title":"Aging Neurosci"},{"key":"10.1016\/j.bbr.2023.114367_bib21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.conb.2019.11.008","article-title":"To stage, or not to stage","volume":"61","author":"Del Tredici","year":"2020","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.bbr.2023.114367_bib22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"issue":"12","key":"10.1016\/j.bbr.2023.114367_bib23","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/S1474-4422(09)70238-8","article-title":"Neuropathological assessment of Parkinson\u2019s disease: refining the diagnostic criteria","volume":"8","author":"Dickson","year":"2009","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.bbr.2023.114367_bib24","doi-asserted-by":"crossref","first-page":"24384","DOI":"10.1038\/s41598-021-03700-2","article-title":"Low plasma serotonin linked to higher nigral iron in Parkinson's disease","volume":"11","author":"Jellen","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbr.2023.114367_bib25","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/0006-8993(90)90733-R","article-title":"Loss of brainstem serotonin and substance P containing neurons in Parkinson\u2019s disease","volume":"510","author":"Halliday","year":"1990","journal-title":"Brain Res."},{"issue":"6","key":"10.1016\/j.bbr.2023.114367_bib26","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/00005072-199111000-00006","article-title":"The neuropathologic basis of different clinical subgroups of Parkinson's disease","volume":"50","author":"Paulus","year":"1991","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.bbr.2023.114367_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2020.147119","article-title":"Compensatory neuritogenesis of serotonergic afferents within the striatum of a transgenic rat model of Parkinson's disease","volume":"1748","author":"Stemick","year":"2020","journal-title":"Brain Res."},{"issue":"Pt. 2","key":"10.1016\/j.bbr.2023.114367_bib28","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/brain\/aws358","article-title":"A progressive dopaminergic phenotype associated with neurotoxic conversion of \u03b1-synuclein in BAC-transgenic rats","volume":"136","author":"Nuber","year":"2013","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.bbr.2023.114367_bib29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0304-3940(03)00295-7","article-title":"Rapid induction of serotonergic hyperinnervation in the adult rat striatum with extensive dopaminergic denervation","volume":"343","author":"Maeda","year":"2003","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.bbr.2023.114367_bib30","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/BF00230443","article-title":"Serotonergic sprouting in primate MTP-induced hemiparkinsonism","volume":"96","author":"Gaspar","year":"1993","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.bbr.2023.114367_bib31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neurobiolaging.2019.03.014","article-title":"Layer-specific axonal degeneration of serotonergic fibers in the prefrontal cortex of aged A53T \u03b1-synuclein-expressing mice","volume":"80","author":"Wihan","year":"2019","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bbr.2023.114367_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.561963","article-title":"Intracellular A53T mutant \u03b1-synuclein impairs adult hippocampal newborn neuron integration","volume":"8","author":"Regensburger","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.bbr.2023.114367_bib33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41398-022-01842-z","article-title":"Human \u03b1-synuclein overexpression in mouse serotonin neurons triggers a depressive-like phenotype. Rescue by oligonucleotide therapy","volume":"12","author":"Miquel-Rio","year":"2022","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.bbr.2023.114367_bib34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13024-019-0306-8","article-title":"Dementia with Lewy bodies: an update and outlook","volume":"14","author":"Outeiro","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.bbr.2023.114367_bib35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.brainres.2008.03.060","article-title":"Dystrophic serotonergic axons in neurodegenerative diseases","volume":"1217","author":"Azmitia","year":"2008","journal-title":"Brain Res."},{"issue":"3","key":"10.1016\/j.bbr.2023.114367_bib36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00401-007-0260-3","article-title":"Rostral raphe involvement in Lewy body dementia and multiple system atrophy","volume":"114","author":"Benarroch","year":"2007","journal-title":"Acta Neuropathol."},{"issue":"3","key":"10.1016\/j.bbr.2023.114367_bib37","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/mds.26874","article-title":"Profile of cognitive impairment and underlying pathology in multiple system atrophy","volume":"32","author":"Koga","year":"2017","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.bbr.2023.114367_bib38","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1093\/brain\/awaa126","article-title":"Hippocampal \u03b1-synuclein pathology correlates with memory impairment in multiple system atrophy","volume":"143","author":"Miki","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.bbr.2023.114367_bib39","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/B978-0-444-53491-0.00005-5","article-title":"Central control of autonomic function and involvement in neurodegenerative disorders","volume":"117","author":"Cersosimo","year":"2013","journal-title":"Handb. Clin. Neurol."},{"issue":"Pt. 7","key":"10.1016\/j.bbr.2023.114367_bib40","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1093\/brain\/awp110","article-title":"Depletion of medullary serotonergic neurons in patients with multiple system atrophy who succumbed to sudden death","volume":"132","author":"Tada","year":"2009","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.bbr.2023.114367_bib41","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/mds.25927","article-title":"Multiple system atrophy: prognostic indicators of survival","volume":"29","author":"Figueroa","year":"2014","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.bbr.2023.114367_bib42","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.parkreldis.2015.05.016","article-title":"Reduced plasma serotonin and 5-hydroxyindoleacetic acid levels in Parkinson's disease are associated with nonmotor symptoms","volume":"21","author":"Tong","year":"2015","journal-title":"Park. Relat. Disord."},{"issue":"1","key":"10.1016\/j.bbr.2023.114367_bib43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0304-3940(93)90111-W","article-title":"Concentrations of serotonin and its related substances in the cerebrospinal fluid of parkinsonian patients and their relations to the severity of symptoms","volume":"150","author":"Tohgi","year":"1993","journal-title":"Neurosci. Lett."},{"issue":"1\u20132","key":"10.1016\/j.bbr.2023.114367_bib44","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000520302","article-title":"Cerebrospinal fluid levels of 5-hydroxyindoleacetic acid in Parkinson's disease and atypical Parkinsonian syndromes","volume":"21","author":"Kaiserova","year":"2021","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.bbr.2023.114367_bib45","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/345132","article-title":"Serotonin transporter availability in early stage Parkinson's disease and multiple system atrophy","volume":"2014","author":"Suwijn","year":"2014","journal-title":"ISRN Neurol."},{"issue":"3","key":"10.1016\/j.bbr.2023.114367_bib46","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1172\/JCI71640","article-title":"Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson\u2019s disease patients","volume":"124","author":"Politis","year":"2014","journal-title":"J. Clin. Investig."},{"issue":"8","key":"10.1016\/j.bbr.2023.114367_bib47","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S1474-4422(19)30140-1","article-title":"Serotonergic pathology and disease burden in the premotor and motor phase of A53T \u03b1-synuclein parkinsonism: a cross-sectional study","volume":"18","author":"Wilson","year":"2019","journal-title":"Lancet Neurol."},{"issue":"19","key":"10.1016\/j.bbr.2023.114367_bib48","article-title":"Progressive loss of raphe nuclei serotonin transporter in early Parkinson\u2019s disease: a longitudinal 123I-FP-CIT SPECT study","volume":"S1353\u20138020","author":"Pasquini","year":"2019","journal-title":"Park. Relat. Disord."},{"issue":"12","key":"10.1016\/j.bbr.2023.114367_bib49","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1002\/mds.28722","article-title":"Serotonergic and dopaminergic lesions underlying Parkinsonian neuropsychiatric signs","volume":"36","author":"Maillet","year":"2021","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.bbr.2023.114367_bib50","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/mds.28971","article-title":"Limbic serotonergic plasticity contributes to the compensation of apathy in early Parkinson's disease","volume":"37","author":"Prange","year":"2022","journal-title":"Mov. Disord."},{"issue":"8","key":"10.1016\/j.bbr.2023.114367_bib51","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1177\/0271678X20982389","article-title":"Parkinson patients have a presynaptic serotonergic deficit: a dynamic deep brain stimulation PET study","volume":"41","author":"J\u00f8rgensen","year":"2021","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.bbr.2023.114367_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2019.101755","article-title":"Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: an 123I-FP-CIT SPECT study","volume":"22","author":"Joling","year":"2019","journal-title":"NeuroImage Clin."},{"issue":"8","key":"10.1016\/j.bbr.2023.114367_bib53","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1007\/s00259-019-04324-5","article-title":"Extrastriatal dopaminergic and serotonergic pathways in Parkinson\u2019s disease and in dementia with Lewy bodies: a 123I-FP-CIT SPECT study","volume":"46","author":"Pilotto","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.bbr.2023.114367_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2019.102062","article-title":"Serotonergic deficits in dementia with Lewy bodies with concomitant Alzheimer's disease pathology: an 123I-FP-CIT SPECT study","volume":"25","author":"van der Zande","year":"2020","journal-title":"NeuroImage Clin."},{"issue":"Pt. 7","key":"10.1016\/j.bbr.2023.114367_bib55","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/brain\/awh485","article-title":"Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease","volume":"128","author":"Scherfler","year":"2005","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.bbr.2023.114367_bib56","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/mds.28295","article-title":"Brain 5-HT1A receptor binding in multiple system atrophy: an [18 F]-MPPF PET study","volume":"36","author":"Meyer","year":"2021","journal-title":"Mov. Disord."},{"issue":"11","key":"10.1016\/j.bbr.2023.114367_bib57","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1002\/mds.29220","article-title":"Serotonin transporter imaging in multiple system atrophy and Parkinson's disease","volume":"37","author":"Chou","year":"2022","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbr.2023.114367_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.autneu.2021.102901","article-title":"The LC-NE system as a potential target for neuromodulation to ameliorate non-motor symptoms in Parkinson's disease","volume":"236","author":"Zaehle","year":"2021","journal-title":"Auton. Neurosci."},{"issue":"4","key":"10.1016\/j.bbr.2023.114367_bib59","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1001\/archneurol.2010.35","article-title":"Serotonin 2A receptors and visual hallucinations in Parkinson disease","volume":"67","author":"Ballanger","year":"2010","journal-title":"Arch. Neurol."},{"issue":"4","key":"10.1016\/j.bbr.2023.114367_bib60","first-page":"1389","article-title":"Blinded SAPS-PD assessment after 10 weeks of pimavanserin treatment for Parkinson\u2019s disease psychosis","volume":"10","author":"Isaacson","year":"2020","journal-title":"J. Park. Dis."},{"issue":"4","key":"10.1016\/j.bbr.2023.114367_bib61","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa2034634","article-title":"Trial of pimavanserin in dementia-related psychosis","volume":"385","author":"Tariot","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbr.2023.114367_bib62","article-title":"Long-term outcomes with pimavanserin for psychosis in clinical practice","volume":"6","author":"Akbar","year":"2022","journal-title":"Clin. Park. Relat. Disord."},{"issue":"1","key":"10.1016\/j.bbr.2023.114367_bib63","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.nbd.2010.05.028","article-title":"Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study","volume":"40","author":"Politis","year":"2010","journal-title":"Neurobiol. Dis."},{"issue":"6","key":"10.1016\/j.bbr.2023.114367_bib64","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1176\/ajp.143.6.756","article-title":"Clinical and biochemical features of depression in Parkinson's disease","volume":"143","author":"Mayeux","year":"1986","journal-title":"Am. J. Psychiatry"},{"issue":"12","key":"10.1016\/j.bbr.2023.114367_bib65","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/mds.22212","article-title":"Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB","volume":"23","author":"Boileau","year":"2008","journal-title":"Mov. Disord."},{"issue":"21","key":"10.1016\/j.bbr.2023.114367_bib66","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1212\/WNL.0b013e3181feb2ab","article-title":"Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures","volume":"75","author":"Politis","year":"2010","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.bbr.2023.114367_bib67","first-page":"1751","article-title":"An open-label, 8-week study of safety and efficacy of pimavanserin treatment in adults with Parkinson's disease and depression","volume":"10","author":"DeKarske","year":"2020","journal-title":"J. Park. Dis."},{"issue":"5","key":"10.1016\/j.bbr.2023.114367_bib68","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/ene.14179","article-title":"Efficacy and safety of 5-hydroxytryptophan on depression and apathy in Parkinson's disease: a preliminary finding","volume":"27","author":"Meloni","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.bbr.2023.114367_bib69","article-title":"Preliminary finding of a randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of 5-hydroxytryptophan on REM sleep behavior disorder in Parkinson's disease","author":"Meloni","year":"2021","journal-title":"Sleep Breath."},{"key":"10.1016\/j.bbr.2023.114367_bib70","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/mds.24983","article-title":"Maintaining glottic opening in multiple system atrophy: efficacy of serotonergic therapy","volume":"27","author":"Ozawa","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbr.2023.114367_bib71","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.parkreldis.2017.12.011","article-title":"Do selective serotonin reuptake inhibitors improve survival in multiple system atrophy?","volume":"48","author":"Coon","year":"2018","journal-title":"Park. Relat. Disord."},{"issue":"7","key":"10.1016\/j.bbr.2023.114367_bib72","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/mds.28569","article-title":"Fluoxetine for the symptomatic treatment of multiple system atrophy: the MSA-FLUO trial","volume":"36","author":"Rascol","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbr.2023.114367_bib73","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2020-324823","article-title":"Early atypical signs and insula hypometabolism predict survival in multiple system atrophy","author":"Grimaldi","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.bbr.2023.114367_bib74","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mds.27882","article-title":"Motor complications in Parkinson's disease: 13-year follow-up of the CamPaIGN cohort","volume":"35","author":"Kim","year":"2020","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"2","key":"10.1016\/j.bbr.2023.114367_bib75","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/mds.28340","article-title":"Serotonergic system impacts levodopa response in early Parkinson's and future risk of dyskinesia","volume":"36","author":"Fu","year":"2021","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.bbr.2023.114367_bib76","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/ana.22097","article-title":"Maladaptive plasticity of serotonin axon terminals in levodopa- induced dyskinesia","volume":"68","author":"Rylander","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbr.2023.114367_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116869","article-title":"Efficacy and safety of 5-hydroxytryptophan on levodopa-induced motor complications in Parkinson's disease: a preliminary finding","volume":"415","author":"Meloni","year":"2020","journal-title":"J. Neurol. Sci."},{"issue":"7","key":"10.1016\/j.bbr.2023.114367_bib78","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.parkreldis.2006.04.002","article-title":"Paroxetine treatment improves motor symptoms in patients with multiple system atrophy","volume":"12","author":"Friess","year":"2006","journal-title":"Park. Relat. Disord."}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432823000852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432823000852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T13:38:13Z","timestamp":1759066693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432823000852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":78,"alternative-id":["S0166432823000852"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2023.114367","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serotonin in synucleinopathies","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2023.114367","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114367"}}